Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 2;14(11):2773.
doi: 10.3390/cancers14112773.

Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment

Susanne Ghandili  1 , Philipp H von Kroge  2 , Marcel Simon  1 , Frank O Henes  3 , Holger Rohde  4 , Armin Hoffmann  4 , Nick Benjamin Lindeman  1 , Carsten Bokemeyer  1 , Walter Fiedler  1 , Franziska Modemann  1   5
Affiliations

Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment

Susanne Ghandili et al. Cancers (Basel). .

Abstract

Despite therapeutic advances in the prevention and treatment of febrile neutropenia, acute leukemia (AL) patients still have considerable febrile neutropenia-related mortality. However, the diagnostic yield of flexible bronchoscopy (FB) and bronchoalveolar lavage (BAL) in acute leukemia patients is unclear. In this retrospective single-center study, we analyzed 88 BAL samples of patients with acute leukemia and pulmonary infiltrates in spite of treatment with broad-spectrum anti-infective agents. The aim was to investigate the impact of FB with BAL on detecting causative organisms, which would result in a change in treatment regimens. The median age was 59 years, and 86% had acute myeloid leukemia. In 47%, pathogens were detectable in BAL fluid (pathogen bacteria, viruses, and fungi in 2, 15, and 18%, respectively), with Aspergillus fumigatus detected most frequently. BAL-guided anti-infective therapy changes were performed in 15%. The detection of herpes simplex and influenza viruses were the main reasons for treatment changes. Despite broad-spectrum anti-infective treatment, in approximately half of all patients, pathogens could still be isolated in BAL samples. However, consecutive changes in anti-infective treatment were considerably less frequent, with most changes performed in patients with Herpes simplex virus and Influenza A detection. The need for FB with BAL in patients with AL receiving broad-spectrum empiric anti-infective treatment should therefore be weighed carefully.

Keywords: acute leukemia; bronchoalveolar lavage; flexible bronchoscopy; pneumonia.

PubMed Disclaimer

Conflict of interest statement

S.G., P.H.v.K., M.S., F.O.H., A.H. and N.B.L. have nothing to declare. H.R. received consulting honoraria from Pfizer, MSD, and Shionogie and received speaker honoraria from Pfizer, MSD, Shinogie, Advanz Pharma, and Infectopharm. C.B. received speaker honoraria from AOK Germany, Bristol Myers Squipp, med update, Merck Serono, Roche Pharma, and Sanofi Aventis; and participated in advisory boards for Astra Zeneca, Bayer Healthcare, Berlin Chemie, Bristol Myers Squipp, GSO Research Organisation, Jansen Cilag, Merck Serono, Merck Sharp Dohme, Novartis, and Sanofi Aventis. W.F. participated in advisory boards for Morphosys, AbbVie, Pfizer, Amgen, Jazz Pharmaceuticals, and Clinigen, received support for meeting attendance from Amgen, Jazz Pharmaceuticals, Daiichi Sankyo Oncology, Bristol-Myers Squibb, and Servier, and received support for medical writing from Amgen, Boehringer Ingelheim, Pfizer, and AbbVie. F.M. received support for meeting attendance from Servier, Abbvie, Incyte, Gilead, Jazz Pharmaceuticals, Novartis, Teva, Pfizer, and Amgen, received support for medical writing from Servier, received research grant from Apis Technologies and Daiichi Sankyo, and received speaker honorarium from Servier, Jazz Pharmaceuticals, and Abbvie.

Figures

Figure 1
Figure 1
Flow chart of study design and population.
Figure 2
Figure 2
Hospital-based anti-infective treatment at time point of flexible bronchoscopy with bronchoalveolar lavage in each patient. All patients included in this study received empiric antibiotic and antifungal treatment for at least 72 h prior to bronchoscopy. The choice of empiric gram-positive targeted therapy and/or application of last-resort antibiotics and the choice of which antifungal agent was administered was at the discretion of the physician.
Figure 3
Figure 3
Detection of pathogenic bacteria, viruses, or fungi in bronchoalveolar fluid and distribution of all detected clinically relevant pathogens by showing rates of detection of bacteria, virus, and fungi, or a combination of them in all 88 cases. (a) Rate of pathogenic bacteria detected in total of all BAL fluids. Non-pathogenic bacteria are named below but not in the figure. (b) Rate of pathogenic viruses detected in total of all BAL fluids. Non-pathogenic viruses were not detected. (c) Rate of pathogenic fungi detected in total of all BAL fluids. Non-pathogenic bacteria are named below but not in the figure.
See this image and copyright information in PMC

References

    1. Klastersky J., de Naurois J., Rolston K., Rapoport B., Maschmeyer G., Aapro M., Herrstedt J. on behalf of the ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann. Oncol. 2016;27((Suppl. S5)):v111–v118. doi: 10.1093/annonc/mdw325. - DOI - PubMed
    1. Taplitz R.A., Kennedy E.B., Bow E.J., Crews J., Gleason C., Hawley D.K., Langston A.A., Nastoupil L.J., Rajotte M., Rolston K.V., et al. Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J. Clin. Oncol. 2018;36:3043–3054. doi: 10.1200/JCO.18.00374. - DOI - PubMed
    1. Biswal S., Godnaik C. Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards. Ecancermedicalscience. 2013;7:310. - PMC - PubMed
    1. Nesher L., Rolston K.V. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection. 2014;42:5–13. doi: 10.1007/s15010-013-0525-9. - DOI - PubMed
    1. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266. doi: 10.1002/cncr.21847. - DOI - PubMed

LinkOut - more resources